SYSTEMATIC REVIEW article
Front. Nutr.
Sec. Nutrition and Microbes
Volume 12 - 2025 | doi: 10.3389/fnut.2025.1612021
The Beneficial Effects of Probiotics on Patients with Coronary Heart Disease: A Systematic Review and Meta-analysis
Provisionally accepted
- Sixth Medical Center of PLA General Hospital, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Coronary heart disease (CHD) is a major global health burden, and emerging evidence suggested that probiotics could improve cardiovascular health by modulating gut microbiota and lipid profiles. However, the efficacy of probiotics remains elusive, indicating the necessity of conducting this meta-analysis. Methods: This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, searching PubMed, EMBASE, and Web of Science databases for retrieving randomized controlled trials (RCTs) on probiotics' effects on lipid profiles (low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG)) in CHD patients. Inclusion and exclusion criteria concentrated on English-language RCTs, and data on study characteristics were extracted. Study quality was assessed using Cochrane and NHLBI tools, and statistical analysis was conducted via R 4.3.2 software.The literature search identified 263 records, yielding 6 RCTs, 5 of which were included in the meta-analyses. For LDL level (n = 278), both fixed-effects and randomeffects models exhibited an overall effect size of 1.25 units (95% confidence interval (CI): -0.62 to 3.12) with a low heterogeneity (I² = 0%), while probiotics-based monotherapy achieved a mean difference (MD) of 13.4105 (95% CI: -8.0670 to 34.8879) versus an MD of 1.1578 for combination therapy (95% CI: -0.7146 to 3.0302). For HDL level (n = 278), the fixed-effects model yielded an MD of -3.8107 (95% CI: -4.2490 to -3.3724) versus an MD of -2.3119 for the random-effects model (95% CI: -4.2290 to -0.3949) with a moderate heterogeneity (I² = 61.6%). Combination therapy demonstrated an MD of -2.9848 (95% CI: -4.7965 to -1.1732), while monotherapy exhibited a non-significant MD of 0.9115 (95% CI: -3.5084 to 5.3314). TG analysis yielded a common effect size of 17.95, with a minimal-to-moderate heterogeneity (I² = 0% to 84.7%).Probiotics, particularly monotherapy for LDL and combination therapy for HDL, exhibited potential to improve lipid profiles in CHD patients. However, further research is needed to address existing limitations and confirm efficacy.
Keywords: MY: Conceptualization, Formal analysis, Methodology, Writing -review & editing, JD: Software, Validation, Writing -original draft, LC: Investigation, Supervision, Writing -review & editing, NZ: Investigation, Supervision, Writing -review & editing Probiotics, coronary heart disease, LDL cholesterol, HDL cholesterol, Triglycerides
Received: 16 Apr 2025; Accepted: 09 Jun 2025.
Copyright: © 2025 Jie, Chen, Zheng and Yang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ming Yang, Sixth Medical Center of PLA General Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.